As of 2024-12-15, the EV/EBITDA ratio of Xvivo Perfusion AB (XVIVO.ST) is 109.60. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. XVIVO.ST's latest enterprise value is 14,411.09 mil SEK. XVIVO.ST's TTM EBITDA according to its financial statements is 131.49 mil SEK. Dividing these 2 quantities gives us the above XVIVO.ST EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 12.5x - 20.0x | 16.7x |
| Forward P/E multiples | 16.8x - 24.0x | 20.8x |
| Fair Price | 65.85 - 218.81 | 137.04 |
| Upside | -86.0% - -53.5% | -70.9% |
| Date | EV/EBITDA |
| 2024-12-13 | 109.60 |
| 2024-12-12 | 107.57 |
| 2024-12-11 | 106.61 |
| 2024-12-10 | 105.17 |
| 2024-12-09 | 107.09 |
| 2024-12-06 | 108.28 |
| 2024-12-05 | 105.41 |
| 2024-12-04 | 108.64 |
| 2024-12-03 | 111.16 |
| 2024-12-02 | 113.91 |
| 2024-11-29 | 111.76 |
| 2024-11-28 | 109.96 |
| 2024-11-27 | 108.76 |
| 2024-11-26 | 106.37 |
| 2024-11-25 | 108.04 |
| 2024-11-22 | 104.93 |
| 2024-11-21 | 103.61 |
| 2024-11-20 | 103.85 |
| 2024-11-19 | 105.05 |
| 2024-11-18 | 103.37 |
| 2024-11-15 | 105.77 |
| 2024-11-14 | 108.64 |
| 2024-11-13 | 105.29 |
| 2024-11-12 | 105.17 |
| 2024-11-11 | 107.92 |
| 2024-11-08 | 104.69 |
| 2024-11-07 | 104.69 |
| 2024-11-06 | 103.61 |
| 2024-11-05 | 104.33 |
| 2024-11-04 | 104.69 |
| 2024-11-01 | 104.09 |
| 2024-10-31 | 104.57 |
| 2024-10-30 | 106.49 |
| 2024-10-29 | 107.45 |
| 2024-10-28 | 115.11 |
| 2024-10-25 | 111.40 |
| 2024-10-24 | 110.56 |
| 2024-10-23 | 113.67 |
| 2024-10-22 | 114.75 |
| 2024-10-21 | 117.27 |
| 2024-10-18 | 117.75 |
| 2024-10-17 | 117.27 |
| 2024-10-16 | 118.23 |
| 2024-10-15 | 117.75 |
| 2024-10-14 | 116.79 |
| 2024-10-11 | 117.51 |
| 2024-10-10 | 114.63 |
| 2024-10-09 | 118.71 |
| 2024-10-08 | 112.12 |
| 2024-10-07 | 112.00 |